Open access
Oct 2026
Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity
Findings suggest the PRMT5/GPX4 axis as a potential therapeutic target and position RK3 as a promising candidate for chemoresistant OS.
Zhen-Dong Xu, Zhuang Du, Qing-Shan Niu et al.
· Frontiers in Pharmacology · 0 citations